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1. Introduction
Frequency of neurodegenerative diseases increase significantly with the age. In the present,
average age is increasing and the number of people over 60 years increases as well. Ageing is
a physiological process; however it seems to be linked with an increasing risk of origin and
development of several diseases including neurodegenerative disorders such as Alzheimer's
disease, Parkinson’s disease, and Huntington’s disease. Exact mechanisms of ageing are still
unclear but experimental evidences support a hypothesis that ageing changes are consequen‐
ces of increasing oxidative damage of organs, tissues, cells and all biomolecules. Oxidative
damage is elevated when production of reactive oxygen species is increased compared to the
physiological condition or a defence ability of organism against attacks of reactive oxygen
species is decreased. Oxidation of specific proteins could play a key role in age associated
damage. A relationship between protein aggregation, oxidative stress and neurodegeneration
remains unclear although neurodegenerative diseases are connected with an origin of protein
deposits. It assumes that protein oxidation and generation of protein aggregates generate a
base for a loss of cell function and a reduced ability aged organisms to resist to physiological
stress. Accumulation of modified proteins, disturbance of ion homeostasis, lipid and DNA
modifications, and impairment of energy production are some of the crucial mechanisms
linking ageing to neurodegeneration. In addition mitochondrial dysfunction plays a key role
in neurology. Damage of mitochondrial electron transport may be an important factor in the
pathogenesis of neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Hunting‐
ton's diseases.
© 2013 Babusikova et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Oxygen is vital for all aerobic organisms and reactive oxygen species (ROS) are formed in cells
as a consequence of aerobic metabolism. Moreover mitochondrial respiration is associated
with inevitable electron leak, resulting in a non-stop production of reactive oxygen species,
such as superoxide anion radical, hydrogen peroxide and hydrogen radical. Universal nature
of reactive oxygen species is underlined by the presence of superoxide dismutase in all aerobic
organisms. Genes involved in detoxification of reactive oxygen species are highly conserved
among eukaryotes and their deficiency could be limit of several diseases and life span.
Oxidative stress is a unique pathophysiological condition resulting from the disrupted balance
between oxidants and antioxidants. Increased level of reactive oxygen species may cause
oxidative damage of all four biomolecules: nucleic acids, proteins, lipids, saccharides. A
progressive grow of oxidative damage is the result of increasing production of reactive oxygen
species and this damage may contribute to the origin and development of several diseases
including neurodegenerative diseases, but on the other hand oxidative damage can be the
consequence of them as well (fig. 1). Cells possess defence systems: enzymatic and non-
enzymatic against ROS. The most important enzymatic antioxidants are: superoxide dismu‐
tase, catalase and glutathione peroxidase but many others enzymes have antioxidant potential.
Figure 1. Reactive oxygen species in the development of disease. As a consequence of imbalance between reac‐
tive oxygen species (ROS) and antioxidant mechanisms (AOM) on the side of reactive oxygen species, oxidative stress
is increasing. Increased level of reactive oxygen species causes increased oxidative damage of biomolecules, an accu‐
mulation of damage, and the development of many diseases.
2. Oxidative damage
Reactive oxygen species (ROS) are necessary for human life. The main characteristics of ROS
are their high effectiveness in a small concentration and their extremely highly reactivity. ROS
are oxidants which can be produced endogenously and exogenously. Potential harmful ROS
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generate in cells under normal physiological conditions in different metabolic pathways and
cell compartments (fig. 2).
Figure 2. The main endogenous sources of reactive oxygen species (ROS) in cell. Organelles such as mitochon‐
dria, peroxisomes, phagocytes and endoplasmic reticulum and enzymes produce ROS during a pursuance their physio‐
logic roles in cell and during metabolism of several components.
Four  from  the  endogenous  sources  (mitochondria,  phagocytes,  peroxisomes,  and  cyto‐
chrome P450  enzymes) are responsible for origin of the majority of oxidants produced by
cells  [5].  The  main  endogenous  sources  of  reactive  oxygen  species  are  mitochondria
which produce reactive oxygen species continuously.  Mitochondria serve mainly as pro‐
ducers  of  energy.  In  normal  aerobic  respiration  mitochondria  utilize  oxygen  that  is  re‐
duced by serial  steps whereby is  produced water.  Mitochondria are the major producer
of reactive oxygen species via incomplete reduction of oxygen by electrons leaked out of
the respiratory chain in the animal and human cells. Mitochondrial oxidative damage can
lead to the release of greater amount of reactive oxygen species and cause increased oxi‐
dative damage of mitochondrial, cytoplasmic and nuclear components what subsequently
may  lead  to  dysfunctional  mitochondria.  Damage  of  mitochondrial  electron  transport
may be an important factor in the pathogenesis of many diseases.
Phagocyting cells are another important endogenous source of oxidants. The main function of
phagocytosis is the defence of host organisms against pathogens. Neutrophils and another
phagocytes attack pathogens by mixture of reactive oxygen species: singlet oxygen (O2•-), nitric
oxide (•NO), hydrogen peroxide (H2O2), hypochlorous acid (HClO) [129]. Chronic virus,
bacterial or parasite infection results in chronic increased phagocyting activity and finally
chronic inflammation, which is a main risk factor for development of several diseases [5], and
raising oxidative damage.
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Peroxisomes are organelles from the microbody family and are present in almost all  eu‐
karyotic cells. They participate in the β-oxidation of fatty acids and in the metabolism of
many others  metabolites.  Certain  enzymes  within  peroxisome,  by  using  molecular  oxy‐
gen,  remove  hydrogen  atoms from specific  organic  substrates,  in  an  oxidative  reaction,
producing hydrogen peroxide.  Hydrogen peroxide  is  degraded by catalase,  another  en‐
zyme in peroxisome.  Peroxisomes contain also xanthine oxidase which produces singlet
oxygen and hydrogen peroxide.
Microsomal cytochrome P450 enzymes are a very large and diverse superfamily of hemopro‐
teins identified from all lineages of life including humans, mammals, birds, fish, plants,
bacteria. They form one of the primary defence system against xenobiotic compounds usually
plant origin. Human cytochrome P450 enzymes are primarily membrane-associated proteins,
located in the inner mitochondrial membrane or in the endoplasmic reticulum of cells. They
modify thousands of endogenous and exogenous compounds by univalent oxidation or
reduction. Induction of these enzymes protects before acute oxidative effects of foreign
compounds or chemicals but also results in production of oxidants.
Although cells possess complex net of antioxidant defence, defence is not completely effective.
Small fractions of pro-oxidants escape from elimination and cause molecular damage. Some
of these damages are irreversible therefore they are accumulated in time and they make base
of functional decline associated with age. Disruption of a balance between the level of reactive
species generated during normal cellular metabolism and the level of endogenous antioxidant,
either due to increased generation of ROS or decreased level of antioxidants, leads to oxidative
damage and to several pathological conditions, including accelerated ageing and neurodege‐
nerative disorders.
Exact mechanisms of reasons for origin of some neurodegenerative diseases are still  un‐
clear  but  experimental  evidences  support  a  hypothesis  that  ageing  is  a  major  risk  and
ageing changes are consequences of increasing oxidative damage. One of the basic prob‐
lems is the analysis of mechanisms that are base of damage. ROS are effective in a very
small  concentrations  and their  half-life  is  very  short.  We still  do  not  have  sensitive  in‐
struments for measurement ROS (concentration and localisation) in living systems. Usual‐
ly  effects  of  ROS are  determined indirect,  by several  markers  of  oxidative  damage (fig.
3). Both localisation and kind of damage are necessary for understanding of neurodegen‐
eration. Oxidative damage may by the most important contribution to ageing and age-re‐
lated diseases. Literature is full of controversy results. Oxidative modification of proteins,
saccharides,  nucleic  acid  (nuclear  and  mitochondrial)  and  lipid  peroxidation  were  ob‐
served in  different  tissues,  cells,  compartments,  including mitochondria  with  advancing
of age. There is no detail information how the higher availability of reactive oxygen spe‐
cies could be translated to an accumulation of oxidized biomolecules so far.
An accumulation of oxidized proteins, disturbance of ion homeostasis, modifications of lipids,
saccharides, proteins and nucleic acids, and impairment of energy production are some of the
crucial mechanisms linking ageing to neurodegeneration. Brain is particularly sensitive to
reactive oxygen species attack and to oxidative damage consequence of several factors:
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• Brain has a high content of unsaturated fatty acid (especially 20:4 and 22:6 fatty acids).
• Brain has high oxygen consumption (20% of using oxygen is consumed by brain).
• In the brain is high concentration of iron and ascorbate (key elements responsible for
membrane lipid peroxidation).
• Brain is to poor of antioxidants and defence mechanisms.
Figure 3. Markers of oxidative damage. Proteins, lipids and DNA are main targets of reactive oxygen species (ROS).
These molecules generate a spectrum of molecules in the condition of oxidative stress which may be estimated for
example in plasma, serum, bronchoalveolar lavage fluid, tissues and in exhalated breath condensate and reflect a dan‐
ger of ROS for a subject in consequence of origin and development of several diseases.
Exclusive using of glucose as a source of energy by brain is responsible for high oxygen
concentrations which are necessary for normal brain function. A predominant quantity of
reactive oxygen species (90-95%) is generated during aerobic metabolism as a by-product in
an electron transport chain of mitochondria. Mitochondrial dysfunction plays a key role in
neurology [8]. A decline in respiratory chain Complex I and Complex IV activity is associated
with ageing [38]. Damage of mitochondrial electron transport may be an important factor in
the pathogenesis of neurodegenerative. Increased oxidative stress in consequence of unpro‐
portional ROS production is considered a main feature in the pathogenesis of neurodegener‐
ative diseases [16, 141]. Apoptosis is an important mechanism of neuronal loss in age-related
neurodegenerative diseases [38, 141]. Neuronal apoptosis in age-associated neurodegenera‐
tive disorders can be triggered by oxidative damage of proteins, lipids and DNA, metabolic
compromise resulting from impaired glucose metabolism and mitochondrial dysfunction, and
over activation of glutamate receptors resulting in disruption of neuronal calcium homeostasis.
Several different kind of oxidative protein and lipid damages were observed in brain during
ageing as well as increased generation of reactive oxygen species [59, 138, 144, 153, 154].
Increasing protein oxidation and lipid peroxidation can participate on the age-related brain
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cell dysfunction. There are many studies demonstrated elevated concentration of different ROS
and decreased antioxidant status during ageing and in neurodegenerative disorders but
majority of them are determined on animal models or cell lines. We are still limited in human
studies especially in the case of neurodegenerative disorders; and ethnicity, environment and
life style may be responsible for controversial results.
2.1. Protein oxidation
One of the important targets of oxidative damage can be proteins which play elementary roles
such as biological accelerators, gene regulators, receptors, transport proteins and structural
components of cells. Oxidative modification of proteins by reactive oxygen species or by other
reactive molecules (e.g. products of lipid peroxidation) is implicated in aetiology or develop‐
ment of many diseases and it can also contribute to secondary damage of other molecules.
Damage of DNA repair enzymes could raise levels of DNA oxidative damage and increase of
mutation frequency. DNA polymerase damage might result in decreasing of fidelity in
replicating DNA. Endogenous proteins are very sensitive to free radical modification as by by-
products of normal metabolic processes or after exposition to oxidative stress in vivo or in
vitro [48, 64, 86]. ROS-associated protein modification can lead to loss of biological functions
and to the change of protein forms. Modified proteins have increased sensitivity to intracellular
proteolysis [176] and they are quickly degraded by endogenous proteases, particularly by
multi-catalytic system [45]. Reactive oxygen species can react directly with proteins or they
can react with molecules such as saccharides and lipids forming reactive products, which
consecutively attack proteins. Reactions are often influenced by redox cycle of metal cations,
particularly by iron and copper. Proteins can go through many covalent changes after exposing
to oxidants [98]. Some of this alternations result from direct attacks of ROS on protein molecule;
meanwhile another changes are produced indirectly [110]. Protein oxidation can lead to the
amino acid side chain residues oxidation. All protein amino acid residues are sensitive to
oxidative damage by hydroxyl radical that is generated by radiation but no all products
generated during oxidation of some amino acid residues were absolutely characterised.
However, tyrosine, phenylalanine, tryptophan, histidine, methionine and cysteine are
preferred target of •OH attack [38]. In consequence of •OH attack of side chains in presence of
oxygen can form hydroperoxides, alcohols and carbonyl compounds [39]. Proteins can contain
after ROS attack new functional groups (hydroxyl and carbonyl groups) [22]. Protein oxidation
can lead to the breaking of peptide bounds (formation of products with lower molecular
weight) and to the formation of protein-protein cross-links (formation of products with higher
molecular weight) and to the protein netting. These changes can result in different secondary
effects including protein fragmentation, aggregation and unfolding. These processes are
ordinarily connected with loss or change of protein activity and function [11, 102]. Increased
oxidative damage of proteins result in:
• an increased production of reactive oxygen species [77],
• a decreased capacity to scavenge reactive oxygen species,
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• an increased sensitivity of damaged proteins to become oxidized as a consequence of
transcriptional and translational errors [1],
• a decreased levels or activities of the proteasome or proteases which degrade oxidized
proteins [24].
2.2. Lipid peroxidation
Lipid peroxidation is an example of oxidative damage of cell membranes, lipoproteins and
other lipid containing structures. This oxidative damage is degenerative process, which affects
cellular membranes under conditions of oxidative stress [136]. Membranes are particularly
sensitive to oxidative damage because they are rich on two or more carbon-carbon double
bonds -C=C- [148]. During lipid peroxidation, polyunsaturated higher fatty acids are damaged
in auto-catalytic, uncontrolled process which result is production of hydroperoxides of
membrane lipids and wide spectrum of secondary metabolites including different aldehydes.
Aldehyde products of lipoperoxidation may interact with mitochondrial membrane lipids and
can change physiochemical state of membrane [150]. The major components of biological
membranes are lipids and proteins. The amount of proteins is increasing with the number of
functions that are on membranes performed. Lipid peroxidation can therefore cause damage
of membrane proteins as well as lipids. Lipoproteins are also target of oxidative damage. Lipid
hydroperoxides are primary products of lipid peroxidation. Dissociation of hydroperoxides
is important from toxicological point of view for two reasons:
• new radicals are generated and ramify radical reactions,
• non-radical products are produced which can be also biologically active.
It was found, that lipid peroxidation produces: unsaturated aldehydes, malondialdehyde, 4-
hydroxy-2-nonenal (HNE) and other products that are cytotoxic and mutagenic and can
damaged other biomolecules [91]. Malondialdehyde arises largely from peroxidation of
polyunsaturated fatty acids with more than two double bonds and it can also arise enzymat‐
ically during eicosanoid metabolism. 4-hydroxy-2-nonenal has toxic property like cell growth
inhibition, genotoxicity, chemotaxic activity and able ability to modify lipoproteins and
promote atherosclerosis [51]. It is able react with nucleofil components largely with metabolites
and proteins contained thiol groups [50]. Effect of HNE is depending on its concentration.
Lipid peroxidation can be overly destructive process in living system. It damages biological
membrane thereby are changed their biophysiological properties. Aldehyde products of
lipoperoxidation reacted with mitochondria membrane lipids and can change physiochemical
state of membrane [28]. Peroxidation of membrane phospholipids is accompanied by change
structural and functional characteristics of membranes. Lipid peroxidation impacts also
function of proteins that are component of biological membranes. Consequence of near
physiological junction lipids and proteins can lead oxidative damage of mitochondrial proteins
to form proteins cross linkage, protein degradation or to lose of their function [166]. Oxidative
damage can be established into proteins with reaction with aldehydes arisen during lipid
peroxidation. For example HNE or malondialdehyde can react with ε-amino group of lysine,
with thiol group of cysteine and with imidazol group of histidine [16].
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2.3. Oxidative damage of DNA
Nucleic acids are particularly sensitive to oxidative damage. There is increasing evidence that
ROS are involved in the development of cancer, not only by direct effects on DNA but also by
affecting signal transduction, cell proliferation, cell death and intracellular communication.
ROS can damage DNA by direct chemical attack of purine and pyrimidine bases and deoxy‐
ribose sugars and also by indirect mechanisms. There is a known more than 20 product of
oxidative damage of the nucleic acids.
Superoxide, nitric oxide or hydrogen peroxide at physiologically relevant levels do not react
with any of DNA or RNA bases or with the ribose or deoxyribose sugars at significant rates.
Particularly hydroxyl radical is known to cause chemical modifications of DNA through the
formation of one strand and two strands breaks and cross linkages with other molecules.
Different saccharides radicals of DNA can arise by abstraction of a hydrogen atom from
2`deoxyribose because all positions in saccharides are susceptible to oxidative damage.
Hydroxyl radical reacts with aromatic rings therefore also nitrogen bases of nucleic acids are
modified. C5-C6 double bonds of pyrimidines and carbon atoms C4, C5, and C8 of purines are
the most sensitive position to oxidative effect of hydroxyl radical and hydroxyl radical abstract
electron and no hydrogen atom [169]. In consequence of ROS attack to nuclear proteins are
generated protein radicals and radicals of base react under formation of DNA-protein cross-
linking.
Mitochondrial DNA (mtDNA) is excessively sensitive on an oxidative damage because
mtDNA is situated near inner mitochondrial membrane, where are formed ROS. Mitochon‐
drial DNA is small and is not protected by histones like nuclear DNA. Mitochondria are able
repair an oxidative damage of mtDNA and that base excise repair pathway plays a dominant
role in mtDNA repair [36]. Damage of mtDNA can be potentially more important like damage
of nuclear DNA because all mitochondrial genome code genes which are expressed whereas
nuclear DNA includes great number of untranscribed sequences [166]. Linnane and co-
workers [101] assume that accumulation of somatic mutations mtDNA is the main origin of
human ageing and degenerative diseases.
3. Antioxidant defence
In consequence, imbalance between pro-oxidant and antioxidant in favour of pro-oxidants and
their harmful effects, oxidative stress is increased. Cells possess antioxidant defence systems:
enzymatic and non-enzymatic [15]. Antioxidants can work at various levels:
• protection the organism from the formation of reactive oxygen species,
• elimination of reactive oxygen species by conversion to un-radical molecules or to less
reactive ROS,
• reparation of damaged molecules and cell structures,
• removing of oxidised molecules.
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The most important enzymatic antioxidants are: superoxide dismutase, catalase and gluta‐
thione peroxidase. Superoxide dismutase (SOD, EC 1.15.1.1) is universal enzymatic antioxi‐
dant. This enzyme is extremely efficient and catalyses the neutralization of superoxide anion
to oxygen and hydrogen peroxide. There are three major families of superoxide dismutase,
depending on the metal cofactor: Cu/Zn (which binds both copper and zinc), Fe and Mn types
(which bind either iron or manganese), and the Ni type, which binds nickel. In humans three
form of SOD are present: cytoplasmic Cu/Zn-SOD (SOD1), mitochondrial Mn-SOD (SOD2),
and extracellular Cu/Zn-SOD (ECSOD, SOD3). Catalase (CAT, EC 1.11.1.6) is a common
antioxidant enzyme responsible for controlling hydrogen peroxide concentrations in cells.
Catalase as an intracellular antioxidant enzyme catalyzes the decomposition of two molecules
of hydrogen peroxide into one molecule of oxygen and two of water and its activity is
genetically determined. Glutathione peroxidases (GPXs, EC 1.11.1.9) are family of enzymes
ubiquitously distributed which have peroxidase activity whose main biological role is to
protect the organism from oxidative damage. Glutathione peroxidases reduce hydrogen
peroxide to water and reduced glutathione and lipid hydroperoxides to their corresponding
alcohols, water and reduced glutathione. Four types of GPXs have been identified: cellular
GPX, gastrointestinal GPX, extracellular GPX, and phospholipid hydroperoxide GPX [161].
Other an essential part of defence mechanism is a super-family of enzymes called glutathione
transferases (GSTs, EC 2.5.1.18). These enzymes are involved in the cellular detoxification of
various electrophilic xenobiotic substances such as chemical carcinogens, environmental
pollutants, drugs and antitumor agents. These enzymes also inactivate endogenous α,β-
unsaturated aldehydes, quinone, epoxides, and hydroperoxides formed as secondary metab‐
olites during oxidative damage. GSTs may reduce reactive oxygen species to less reactive
metabolites and protect organism against consequences of lipid peroxidation. Heme oxygen‐
ase (heat shock protein 32, HO; EC 1.14.99.3) plays an important role in organism defence to
oxidative stress [114] and inflammation [111]. There are known three isoforms of HO: HO-1,
HO-2, and HO-3. HO-1 is activated by a lot of inflammatory mediators, reactive oxygen species
and by other stimuli [109, 135]. Upregulation of HO-1 is accepted as a sensitive marker of
oxidative stress. Oxidative modified DNA can be repaired by several enzymes such as
glycosylases: 8-oxoguanine-DNA-glysocylase (OGG1, EC 4.2.99.18), Nei-like protein 1 and 2
(NEIL, EC 4.2.99.18); Apurinic/apyrimidinic endonuclease 1 (APE 1, EC 4.2.99.18), X ray repair
cross-complementing group 1 (XRCC 1, EC 4.2.99.18) and poly(ADP-ribose) polymerase-1
(PARP 1, EC 2.4.2.30). OGG1 removes 8-oxoguanine paired with a cytosine. Human OGG1
gene consists of eight exons which can be alternatively spliced to produce different isoforms.
The most abundant mRNAs of OGG1 are type 1a and 2a. These two isoforms are ubiquitously
expressed in human tissues.
4. Alzheimer`s disease
Ageing is the main risk factor of neurodegenerative disorders. Approximately 5% of people
in age 65 years have Alzheimer`s disease (AD) and the prevalence of this disease increases
with increasing age from 19% to 30% after 75 years of age. Overall, 90-95% of Alzheimer`s
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disease represents a sporadic form and 5-10% represents familiar form. Alzheimer`s disease
is neurodegenerative disorder characterised by cognitive failures, impairment of memory and
by dramatic changes in behaviour. AD symptoms may include:
• loss of memory,
• difficulty in finding the right words or understanding what people are saying,
• difficulty in performing previously routine tasks, and activities,
• problems with language,
• personality and mood changes.
Although the cause or causes of Alzheimer’s disease are not yet known, most experts agree
that AD, like other common chronic conditions, probably develops as a result of multiple
factors rather than a single cause.
Figure 4. Processing of amyloid precursor protein (APP). Non-amyloid pathway of APP starts by α-secretase cleav‐
age and continues by γ-secretase. Non toxic a soluble fragment of amyloid precursor protein (sAPPα), a small peptide
(p3) and an amyloid intracellular domain (ACID) are produced. Amyloid pathway starts with β–secretase cleavage and
after that it continues by γ–secretase. A soluble fragment of amyloid precursor protein (sAPPβ), a toxic amyloid β pep‐
tide (Aβ) and an amyloid intracellular domain are generated. Amyloid β peptide can be degradated or accumulated
and therefore can be responsible for generation of amyloid plaques.
For Alzheimer`s disease many neurochemical and pathological changes are characteristic
such as gliosis, tissue atrophy caused by loss of synapses which is the most striking in fron‐
tal and temporal parts of brain cortex and by formation of two main protein clusters in ex‐
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tracellular and intracellular region of brain. Extracellular deposits or senile amyloid plaques
occur the most frequently in neocortex. Primary they are consisting of 4 kDa, 40-42 amino
acid polypeptide chain called amyloid β peptide (Aβ) [66]. Intracellular deposits represent
neurofibrillar tangles which are generated from filaments of microtubullar hyperphosphory‐
lated tau protein [4, 70, 99]. Amyloid plaques are example of a specific damage that is char‐
acteristic for AD while neurofibrillar tangles are present in different neurodegenerative
pathological situations [134]. Created aggregates are involved in a process which leads to
progressive degeneration and to neuron death. In the past decade, a significant body of evi‐
dence has pointed the attention to the amyloid processing of amyloid precurcor protein -
“amyloid cascade” (fig. 4). This event is the major causative factor in AD.
Pathogenesis of AD is complex and involves many molecular, cellular, biochemical and
physiological pathologies [9]. Alzheimer`s disease is a characteristic process with identifiable
clinical state which are in a continuity with normal ageing process. It is a multifactorial disease
and genetic as well as environmental factors are included in its pathogenesis. Whereas majority
of AD is sporadic 5% is caused by mutations (familiar AD). There was observed a large loss of
synapses and a neuronal death in a part of brain which is crucial for cognitive function
including cerebral cortex, entorhinal cartex and hippocampus. Senile plaques created by
deposits of amyloid fibres were localized in the brain.
4.1. Oxidative damage and Alzheimer`s disease
Reactive oxygen species probably play an important role in the generation of amyloid plaques,
the development of neurofibrillary tangles and the neurodegenerative process itself. Age-
related accumulation of reactive oxygen species results in damage to nuclear and mitochon‐
drial DNA, lipids (lipid peroxidation), proteins (protein oxidation), and sugars (advanced
glycosylation end products). Oxidative damage caused by reactive oxygen species can account
for the vastly heterogeneous nature of Alzheimer`s disease. Several different kind of oxidative
protein and lipid damages were observed in brain during ageing as well as increased gener‐
ation of reactive oxygen species [1, 24, 136, 147, 150]. We have found increased lipid peroxi‐
dation, accompanied by accumulation of conjugates of lipid peroxidation products with
proteins, formation of dityrosines, loss of sulfhydryl groups and change in ANS (fluorescent
probe 1-anilino-8-naphthalenesulfonate) in the ageing rat brain [7]. Keller et al. [91] observed
that 4-hydroxy-2-nonenal damage a glutamate transport in synaptosome and mitochondrial
function in brain. Increasing lipid peroxidation can participate on the age-related brain cell
dysfunction. Recently, several reports have suggested that mitochondrial abnormalities and
oxidative stress play a role in sporadic Alzheimer`s disease [26, 89, 132, 158, 181]. In brain tissue
from Alzheimer`s disease patients, there are increased levels of markers of oxidative stress,
including oxidized proteins, membrane lipids, and DNA [121, 127, 147, 148]. Oxidative
modification of biomolecules is a marking process for the targeting of proteases. In the process
of ageing there is a marked decrease in protease activity, damaged molecules can be cumulated
with age and it may contribute to the age-related neurodegenerative diseases, including
Alzheimer`s disease.
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Brain and cerebral blood vessel deposits of amyloid β peptide are the main signs of Alzheimer`s
disease. Experimental and clinical studies showed an causal relationship between an accu‐
mulation of amyloid β peptide and origin of Alzheimer`s disease [25, 63, 73]. An abnormal
production of amyloid β peptide or disturbed amyloid β peptide degradation can cause a
pathological accumulation of amyloid β peptide and subsequent production of amyloid
plaques [182]. It is suggested hypothesis that amyloid β peptide cause neuronal damage and
cognitive failure via the generation of reactive oxygen species, mitochondrial oxidative
damage, synaptic failure, and by inflammation changing in the brains of Alzheimer`s disease
patients [133, 140, 158, 160]. Several in vitro studies have shown that synthetic amyloid β
peptide facilitates the production of reactive oxygen species [12, 78, 132]. It was observed
increased levels of soluble amyloid precursor protein in plasma and cerebrospinal fluid with
advancing age [88, 106]. Increased level of soluble amyloid precursor protein may be a sorce
of amyloid β peptide in the brain and vessels. Pluta et al. [126] demonstrated a transit of
amyloid β peptide through the blood brain barrier. Expression of amyloid precursor protein,
α-secretase, β-secretase, enothelin-converting enzyme, neprilysin as well as insulin-degrading
enzyme was demonstrated at the brain barrier system [35]. It is possible that 80% of amyloid
plaques in transgenic models Alzheimer`s disease [44] and 90% of human amyloid plaques is
in a contact with capillaries [87]. Transit of amyloid β peptide or fragments of amyloid
precursor protein from blood to the endothelial cells and brain parenchyma can cause changes
in the vascular elasticity [127, 162] or can have direct pathological implications in the brain
tissue. Changes in the brain blood vessels after brain attack or during the ageing process can
cooperate in the pathogenesis and development of Alzheimer`s disease. Beta-secretase
(BACE1) expression and its mediated β-site amyloid precursor protein cleavage activity
appear to be tightly coupled to mitochondrial function. Beta-secretase upregulation may be a
common consequence in various potential Alzheimer`s disease-related etiological conditions
that involve energy insufficiency and/or oxidative stress [174]. Post mortem analysis of
Alzheimer`s disease patients showed increased level of β-secretase [100, 163] and it can be
responsible for an accumulation of amyloid plaques [179] and amyloid cascade. Reactive
oxygen species that are generated due to ageing can activate β-secretase and facilitate the
cleavage of amyloid precursor protein. Amyloid β peptide can be toxic for organism not only
for its accumulation and amyloid plaques generation but also for possibility to increase
oxidative stress and oxidative damage, to inhibit complexes of respiratory chain in mitochon‐
dria, and to inhibit enzymes of Krebs cycle [117, 132, 133, 147, 148]. However clear and exact
mechanisms interface between amyloid β peptide and increased oxidative damage are
unknown. Oxidative damage of amyloid degrading enzymes can be result of pathological
changes of Alzheimer`s disease as well as a contributing factor to amyloid β peptide accumu‐
lation and generation of amyloid plaques. During ageing we observed protein and lipid
oxidative damage that was caused by increased production of reactive oxygen species and
insufficient or inadequate antioxidant defence. Age-related increasing production of reactive
oxygen species could be one of a key factor leading to the age-related diseases, including
neurodegenerative disease. Elevated oxidative damage and accumulation of amyloid deposits
can have repercussion on deepened oxidative damage, preference of amyloid processing of
amyloid precursor protein and development of Alzheimer`s disease.
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4.2. Alzheimer`s disease and polymorphism in antioxidant enzymes
Oxidative damage is one of the mechanisms which results in stimulation of the amyloid
pathway of APP processing therefore genes of antioxidant enzymes could present another
group of candidate genes. Superoxide dismutase represents the most important part of an
active antioxidant defence. The genes encoding SOD1, SOD2, SOD3 are located in different
chromosomes and in all of them polymorphisms have been described. SOD1 is encoded on
21q22.1, SOD2 on 6q25.3, and SOD3 on 4p16.3-q21. Regulation of SOD genes plays a crucial
role in balancing the reactive oxygen species concentration. In SOD1 has been observed
substitution of A to C at the non-coding position 35. This polymorphism influence SOD1
activity [56]. Substitution T to C at position 24, resulting in a valine to alanine substitution at
amino acid 16 has been identified in SOD2. In SOD3 gene has been identified three single
nucleotide polymorphism: alanine to threonine substitution at amino acid 40, phenylalanine
to cysteine at amino acid 131, and finally the most studied polymorphism which represents
substitution of arginine to glycine at amino acid 213. It has been observed no linkage between
AD polymorphism in SOD1 [37, 105]. It was observed that three polymorphisms in SOD2 can
be associated with development of AD [173].
Catalase is a common antioxidant enzyme responsible for controlling hydrogen peroxide
concentrations in cells. The catalase gene is located on chromosome 11p13. There are known
different polymorphisms of this enzyme in coding regions [67, 93] and in non-coding regions
as well [27, 58, 68, 93, 164, 180]. A common polymorphism in the promoter region of the catalase
gene consists of a C to T substitution at position -262 in the 5' region [58], which is thought to
result in reduced activity. Catalase gene polymorphism does not confirm a protective role in
AD patients.
Glutathione transferases have historically also been called glutathione-S-transferases, and it is
this latter name that gives rise to the widely used abbrevation, GST. Three major families of
proteins the cytosolic, mitochondrial and microsomal (membrane-associated proteins in
eicosanoids and glutathione metabolism, MAPEG) are known. In some organisms expression
of GSTs are upregulated by exposure to prooxidants [6, 41, 167]. Seven classes of cytosolic
glutathione transferases are recognising in mammals (Alpha, Mu, Pi, Sigma, Theta, Omega,
and Zeta) [76]. At least 16 cytosolic GST subunits exist in human and display polymorphisms,
and this is probably to contribute to interindividual differences in responses to diseases and
xenobiotics. GSTM1 is one of the genes encoding the Mu class of enzymes. Gene for GSTM1
has been mapped to glutathione transferase mu gene cluster on chromosome 1p13.3. Three
polymorphisms of GSTM1 have been identified: a substitution (GSTM1A and GSTM1B) and
a deletion [131, 175]. The alleles of the substitution variant differ by C to G transition at base
position 534, resulting in a lysine to asparagine substitution at amino acid 172 [34, 75]. There
is no evidence to date that GSTM1A and GSTM1B alleles are functionally different from one
another; thus these alleles are typically categorized together as a single functional phenotype.
Other polymorphism is a deletion – GSTM1 null variant that results in a lack of functional gene
product and null genotype of GSTM1 was shown as a risk factor in Italian AD patients. The
GSTT1 gene is located at 22q11.2. Absence of both alleles for this gene represents null variant
analogous to GSTM1. Deletion of whole gene results in the lack of enzymatic activity [152].
Oxidative Changes and Possible Effects of Polymorphism of Antioxidant Enzymes in Neurodegenerative Disease
http://dx.doi.org/10.5772/54619
433
Gene for GSTP1 is one of the most intensive studying genes of glutathione transferase family
and has been mapped on chromosome 11q13 and comprising nine exons. There are known
two polymorphisms of GSTP1: substitution of isoleucine to valine at amino acid 105 and
alanine to valine at amino acid 114, demonstrating different catalytic efficiencies due to
changes in the active site [3]. Polymorphism in GSTP1 may represent risk factor for AD and
with advancing age [125, 151]. Presence of gene for GSTM1 and GSTT1 could be a protective
factor [125, 157].
The GPX1 gene is located in the 3p21 locus; the pro198leu polymorphism involves a change
of thymine (T) for cytosine (C), which leads to the substitution of leucine (leu) for proline (pro),
whose recessive allele leu has been linked to 70% reduction of enzyme activity. The leucine
allele of GPX1 may be a possible risk factor [118].
Subjects carrying the HO-1 (-413) TT genotype might show a higher AD risk due to their genetic
inability to induce a more effective HO-1 protective response [83]. Authors showed that an AD
risk effect of HO-1 (−413) TT genotype is only apparent in the presence of liver X receptor (LXR)
LXR-β (intron 2) TT, LXR-β (intron 5) AA, or LXR-β (intron 7) TT genotypes. No genetic
association between AD and polymorphisms of heme oxygenase 1 and 2 were observed in a
Japanese population [143]. A (GT)n repeat in the human HO-1 gene promoter region is highly
polymorphic, although no particular alleles are associated with AD or PD [92].
The DNA base excision repair (BER) pathway is the major pathway responsible for removing
oxidative DNA damage caused by oxidative reagents and alkylation and thus protects cells
against the toxic effects of endogenous and exogenous agents and this pathway is of particular
importance in postmitotic tissues such as brain. The first step in the BER pathway is recognition
and removal of the damaged base by a DNA glycosylase. A variety of glycosylases have
evolved to recognize oxidized bases, which are commonly formed by reactive oxygen species
generated during cellular metabolism. One of them is 8-oxoguanine-DNA-glysocylase
(OGG1). The most common polymorphism of OGG1 is in this gene substitution of serine (Ser)
for cysteine (Cys) at codon 326 in exon 7. The variant homozygote is associated with reduced
enzymatic activity [94]. Allele and genotype frequencies of OGG1 were equally distributed
between AD patients and healthy subjects [32, 115]. The Arg46Gln polymorphism of OGG1 is
also not associated with the pathogenesis of AD [47]. Mao et al. [104] identified in AD patients
deletion in OGG1 and their results suggest that defects in OGG1 may be important in the
pathogenesis of AD in a significant fraction of AD.
Apurinic/apyrimidinic endonuclease 1 (APE1) is an enzyme involved in BER pathway. Its
main role in the repair of damaged or mismatched nucleotides in DNA is to create a nick in
the phosphodiester backbone of the AP site created when DNA glycosylase removes the
damaged base. There are four types of AP endonucleases that have been classified according
to their sites of incision. Genetic polymorphism has been identified in APE1 gene and associ‐
ated with cancer risk. One of the most studied polymorphism is Asp148Glu. No association
was found in AD patients [115].
X-ray repair cross-complementing-1 (XRCC) is a protein, which plays a coordinating role for
consecutive stages of the BER system and interacts with several proteins of BER including
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hOGG1, APE1, DNA polymerase β (pol β) and DNA ligase IIIα [115]. XRCC1 is recruited to
the site of repair till the last stage of ligation, regulating and coordinating the whole process.
More than 60 single nucleotide polymorphisms (SNPs) XRCC1 polymorphisms are known but
the most common polymorphisms in XRCC1 gene are: Arg149Trp, Arg280His, and Arg399Gln,
and are associated with decreased function of XRCC1. It is unlikely that the XRCC1 Arg194Trp
polymorphism plays a major role in the pathogenesis of late-onset AD in elderly Han Chinese
[130] but positive association was found in Turkish population [46]. Arg280His, and
Arg399Gln were not associated with AD [115].
5. Parkinson´s disease
Parkinson´s disease (PD) was firstly described by James Parkinson in 1817. It is the second
most common neurodegenerative disease which affects approximately 1% of the human
population aged 65 and more [80]. PD is slowly progressed disorder characterized by selective
degeneration and loss of dopaminergic neurons in the substantia nigra (SN) pars compacta region
of the midbrain, as well as with the appearance of intracytoplasmic inclusions known as Lewy
bodies [30]. Among clinical symptoms of the disease belong rigidity, resting tremor, bradyki‐
nesia and postural imbalance [139]. Beside motor dysfunctions, as the major clinical features,
non-motor symptoms, such as sleep disturbances, dementia and depression may be present
as well [177].
Familiar PD represents only 5-10% of the total cases of PD. Recently, several gene mutations
have been linked with rare familiar forms of PD (e.g. α-synuclein, parkin, nuclear receptor-
related 1). The most important in early-onset familiar PD is the parkin gene [40]. So far no
genetic changes are definitely connected with sporadic or idiopathic form of the disease.
However, the prevalent form of PD appears to be multifactorial and a combination of envi‐
ronmental and genetic factors, together with ageing, may contribute to the development of the
disease. Biochemical abnormalities that have been detected in sporadic PD include: oxidative
stress [108, 124, 168], mitochondrial and proteasomal dysfunction [116, 142] and glutathione
depletion [10, 177].
5.1. Oxidative damage and Parkinson´s disease
Although the primary cause of PD is still unknown, oxidative stress together with mitochon‐
drial dysfunction are thought to be significantly implicated in the neurodegenerative process.
Excessive formation of reactive oxygen and nitrogen species in PD may damage cellular
components such as lipids, proteins and DNA. Increased lipid peroxidation, measured by
increased amounts of malondialdehyde [42] and 4-hydroxynonenal, as well as increase in the
extent of protein oxidation and elevated concentration of 8-hydroxy-2´-deoxyguanosine, a
product of DNA oxidation [84], in SN provides direct evidence of oxidative damage [43].
Since  majority  of  all  oxygen  is  used  in  mitochondria,  electron  transport  chain  is  major
source of free radicals. Recent research confirmed that about 1-2% of total molecular oxy‐
gen is converted into reactive oxygen species [23].  Post-mortem studies on patients with
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PD have revealed a specific decrease in the activity of NADPH dehydrogenase (complex
I). The alterations in complex I activity were not detected in other regions of the brain, as
well as in other neurodegenerative diseases [142]. Complex I deficiency could contribute
to neurodegeneration in PD not only due to decreased ATP synthesis but also increased
ROS production [11, 137]. Van der Walt et al. [165] also published that the 10398G poly‐
morphism within NADH dehydrogenase 3 may provide significant protection against de‐
veloping PD in Caucasian populations.
Alternatively, ROS may arise during metabolism of dopamine. Autooxidation of dopamine
and its polymerization into neuromelanin produces electrophilic semiquinones and quinones,
which can contribute to ROS production, especially superoxide anion radicals [60]. It is also
known that dopamine is able to coordinate iron and generate Fe2+, providing an important
source of hydroxyl and superoxide radical production [13]. In generally, elevated iron levels
were observed in substantia nigra in PD [149]. A major source of increased iron levels during
PD is microglial activation which induces iron release and free radical production [123]. Free
iron may promote already mentioned autooxidation of dopamine [14]. Oxidative stress
induced by elevated levels of free iron also appears to promote α-synuclein (a prominent
component of Lewy bodies) aggregation, the major histopathological hallmark of PD [75].
Important role in protection of dopaminergic neurons against oxidative stress plays the
antioxidant molecule glutathione (GSH). GSH removes H2O2, which is produced during
cellular metabolism. Perry et al. [121] firstly reported decreased levels of total GSH in autopsied
brains from PD patients. Total GSH is reported to be decreased by 40-50% specifically in nigral
dopaminergic neurons [119]. GSH depletion also appears to correlate with the severity of the
disease and is the earliest known marker of oxidative stress and indicator of degeneration of
nigral neurons [85]. On the other hand, Mythri et al. [108] observed 3-5 fold increase in total
GSH levels in all the non-SN regions of tested PD brains compared to control samples. On the
contrary, they found no significant changes in the levels of protein carbonyls, as markers of
protein oxidation, or nitrosative stress markers. According to these results, they expected that
specific signals from the degenerating dopaminergic SN neurons might induce elevated levels
of GSH and such prevent oxidative damage [108]. Beside GSH, other antioxidant activities are
altered in the SN. The levels of antioxidant enzymes, such as superoxide dismutase, catalase,
glutathione peroxidase and glutathione reductase, were found to be changed in SN [168].
5.2. Parkinson´s disease and polymorphism in antioxidant enzymes
Current research shows that ROS and oxidative damage are part of pathological processes
during PD, but it remains to be determined whether this is a primary event or a consequence
of other cellular dysfunctions. Analysis of polymorphisms of detoxifying enzymes may help
to clarify whether PD may be caused by a genetic predisposition to oxidative stress.
Among antioxidant enzymes, superoxide dismutase (SOD) represents the first line of defence.
From three different SOD isoenzymes, SOD2 appears to be the most relevant in PD because of
its mitochondrial localization. Several research groups confirmed that SOD2 (Ala9Val)
polymorphism is not significantly associated with PD in Caucasian population [52, 69, 146].
On the other hand, some studies, especially on Asian population, found higher Ala allele
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frequency in the group of PD patients [57, 172]. Observed results might be explained by ethnic
differences in genotypes frequencies.
Little is known about the association of catalase polymorphisms and PD. However, Parboo‐
singh et al. [113] observed no connection between mutations of catalase gene and PD.
Glutathione transferases (GST) are the most studied phase II detoxification enzymes. Activity
of GST was observed to be reduced in substantia nigra of PD [145]. Studies of GST polymor‐
phisms and PD yielded mixed results. Several studies confirmed positive association between
GSTM1 and GSTT1 null genotypes and higher risk of PD [120, 157]. On the other hand, other
studies found no association [90, 171]. Similarly, GSTP1 was detected to have only a minor role
in PD [90,, 171]. However, Wahner et al. [90] noted a 32% risk reduction among Caucasian PD
patients carrying at least one GSTO1 and GSTO2 variant allele.
Markedly elevated expression of heme oxygenase 1 was observed in PD and it has been shown
that its overexpression may protect neurons against oxidative stress-induced toxicity [81].
However, Funke et al. [61] found no association of (GT)n fragment length polymorphism in
the promoter region, as well as three other coding SNPs with PD.
Since increased 8-oxo-guanine levels have been observed in PD patients, still more attention
is paid to analysis of genetic polymorphisms of oxoguanine DNA glycosylase (OGG1), which
removes oxidized guanine from DNA. Coppede et al. [33] published that hOGG1 Ser326Cys
polymorphism is not associated with sporadic form of PD.
6. Huntington`s disease
Huntington`s disease (HD) is an autosomal dominant inherited neurodegenerative disorder
of the central nervous system. Worldwide prevalence of HD is 5 to 8 per 100,000 people with
no gender preponderance [74]. HD is characterized by cognitive and memory dysfunctions,
weight loss, and choreiform movements. It is caused by an expansion of a polymorphic three
nucleotide repeat sequence CAG in the exon 1 of the gene coding for the protein huntingtin
(htt) on chromosome 4 (4p16.3) [82]. Wild type htt may exert a variety of intracellular functions
such as: protein trafficking, vesicle transport and anchoring to the cytoskeleton, clathrine-
mediated endocytosis, postsynaptic signaling, transcriptional regulation, and anti-apoptotic
function [65]. For instance, htt is involved in fast axonal transport, enhancing vesicular
transport of brain-derived neurotrophic factor along microtubules [62, 159]. The protein htt
consists of a series of CAG repeats coding for glutamine residues (polyQ) followed by two
short stretches of prolines. Normally, the number of the polyglutamine repeats is 10-29
(median, 18). By contrast, HD patients have expanded numbers of CAG repeats, from 39 to
121 (median, 44). Expanded repeats cause a conformational change in the htt promoting the
formation of intracellular aggregates, mainly in medium spiny neurons where the expression
of huntingtin is elevated. The number of CAG repeats is inversely correlated with the age of
disease onset, and disease progression is rapid in patients with more CAG expansion [96]. In
brain, the most remarkable changes are found within the striatum, there is a gradual atrophy
of the caudate nucleus and putamen [170].
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6.1. Oxidative damage and Huntington`s disease
The generation of reactive oxygen species and the consequent oxidative stress is thought to
play a pivotal role in the neurodegeneration observed in HD [53, 71] (Ferrante, Grunewald).
Several lines of evidence suggest that not only increased oxidative stress, but also protein
metabolism impairment, mitochondrial dysfunction, and they interplay contribute to neuronal
dysfunction in HD [18, 19, 112, 128].
DNA fragmentation is significantly increased in human HD patients and correlates with the
length of CAG repeats [20]. The oxidation of DNA leads to the formation of the metabolite 8-
hydroxy-2`-deoxyguanosine (OHdG) which is a direct result of free radical activity [128].
Significant increases of OHdG levels, coming from nuclear DNA, occur in the caudate nucleus
and parietal cortex in postmortem tissue of HD patients [18, 128]. In addition, increased
oxidative damage to DNA is present in serum from HD patients [29, 79. Moreover, the
improvement of elevated OHdG by creatine treatment suggests OHdG as a promising
peripheral biomarker [79]. These findings are in consensus with the elevated levels of OHdG
that occur in other neurodegenerative diseases in which oxidative stress is implicated as a
pivotal pathogenic mechanism [55]. Nevertheless, some research groups have not confirmed
changes in OHdG levels in HD patients [2].
Elevated levels of malondialdehyde (MDA), a marker of lipid peroxidation, have been
documented in HD brain [72]. Elevated levels of MDA have also been shown in the peripheral
blood of HD patients, and preliminary results suggest that the levels of lipid peroxidation
(MDA level) appear to be correlated to disease severity [29, 155]. Reduced activities of
erythrocyte glutathione peroxidase and Cu/Zn-superoxid dismutase in HD patients implicate
that the defense mechanism is impaired in peripheral blood cells of HD. Because of ubiquitous
expression of huntingtin, the peripheral abnormalities may reflect the same consequences to
mutant huntingtin in the brain [29]. An abnormal accumulation of lipofuscin, product of
unsaturated fatty acid lipid peroxidation, has been proven in HD patients [17]. Supplemental
markers of oxidative damage, as for example inducible form of heme oxygenase, 3-nitrotyro‐
sine, and above mentioned malondialdehyde, are elevated in human HD striatum and cortex
compared with age-matched control brain specimens [19, 54].
The primary source of reactive oxygen species in neurons is mitochondria. Mitochondrial
dysfunction in HD is closely associated with oxidative stress. In was first reflected that here
was an energetic impairment in HD, because HD patients exhibit profound weight loss despite
continual caloric intake [20, 21]. Lowered glucose utilization in striatum of HD patients early
stages prior to pronounced striatal atrophy [97]. Mitochondrial functional abnormalities were
observed, such is a defect in succinate dehydrogenase in the caudate of postmortem HD brains.
Subsequent studies confirmed that there was a significant decrease in complex II activity in
the caudate nucleus, in complex III activity in the caudate and putamen, and of complex IV in
the putamen of HD brains [18, 72, 103].
Plasma lipid peroxide and lactate concentrations as indicators of oxidative stress and mito‐
chondrial dysfunction, were significantly elevated in HD patients. On contrary, aspartate and
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glutamate aminopeptidase activities were significantly reduced in HD patients. These changes
may be related to the progression of the disease [49].
6.2. Polymorphisms and Huntington`s disease
Besides CAG repetition in huntingtin gene, there are 2 genetic polymorphisms in the full-
length htt gene. One of them, named CCG polymorphism is located in the first proline-rich
fragment, second one is delta 2642 glutamic acid polymorphism. Previous studies have shown
that alleles with 7 or 10 repeats are predominant in CGG polymorphism, but the distribution
from among ethnics is variable. In western population is strong association between the 7
repeat CCG allele and HD [156]. On contrary, in Japanese population has been shown
association with the 10 repeat CCG allele and HD [107]. Latest study performed on Chinese
population compared the clinical features between the 7 and 10 repeats CCG alleles, but did
not find any statistical significant results [178].
It was proposed a model that somatic expansion of CAG repeats in HD cells might contribute
to disease onset and progression of HD and is mediated by the DNA repair oxoguanine
glycosylase 1 (OGG1) enzyme [95]. This enzyme removes 8-oxoguanine from the DNA. Study
of the hOGG1 Ser326Cys polymorphism performed on 91 patients showed that bearers of
mutant Cys allele appear to have an increased number of the CAG repeats of the expanded
HD allele. Since this is the first evidence of an association between the hOGG1 genotype and
both CAG repeat length and age at onset of the HD, for confirmation, further studies are
required [31].
7. Conclusions
Population ages therefore neurodegenerative diseases are in a centre of interest. Several studies
showed that missing antioxidant genes may have negative effect on central nervous system
and may represent a risk for development of neurodegenerative diseases. Unfortunately
majority of results are from animals and cell tissue studies. Animal studies, in vitro and ex
vivo studies are full of positive effects of single antioxidant gene overexpression such as
superoxide dismutase, catalase and antioxidant therapy may represent promising treatment.
Molecular and genetic analyses represent a new potential for neurodegenerative diseases
studying. The role of gene polymorphisms and many others gene polymorphisms as risk
factors for the occurrence of neurodegenerative diseases are still controversial. Moreover
impact of gene polymorphisms can depend on several different factors, especially for neuro‐
degenerative diseases, such as ethnicity, social environment, life style. We need new studies
for clear determination of antioxidant gene polymorphisms. Moreover multiple genotype
analyses are necessary as well because a single gene polymorphism can be without relationship
to increased risk of neurodegenerative disorders but the combination of gene polymorphisms
may have significant effect, positive or negative.
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